Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
145.91B
Market cap145.91B
Price-Earnings ratio
19.70
Price-Earnings ratio19.70
Dividend yield
6.69%
Dividend yield6.69%
Average volume
34.29M
Average volume34.29M
High today
$25.85
High today$25.85
Low today
$25.58
Low today$25.58
Open price
$25.80
Open price$25.80
Volume
30.38M
Volume30.38M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $25.60. The company's market cap stands at 145.91B, with a P/E ratio of 19.70 and a dividend yield of 6.7%.

On 2026-06-10, Pfizer(PFE) stock moved within a range of $25.58 to $25.85. With shares now at $25.60, the stock is trading +0.1% above its intraday low and -1.0% below the session's peak.

Trading activity shows a volume of 30.38M, compared to an average daily volume of 34.29M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $28.75 and a low of $23.11.

PFE News

TipRanks 44m
Top Pfizer Executive Quietly Unloads a Chunk of Company Stock

New insider activity at Pfizer ( (PFE) ) has taken place on June 10, 2026. Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly...

TipRanks 10h
Pfizer Steps Up in Obesity Race With New Mid-Stage SOLIS-1 Trial

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is advancing a phase 2b trial called SOLIS-1 to test new weight-loss dr...

TipRanks 10h
Pfizer’s Next-Gen Pneumococcal Shot: What a Fresh Trial Update Means for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has completed a Phase 1/2 study called “A Phase 1/2, Randomized, Double...

Analyst ratings

59%

of 29 ratings
Buy
34.5%
Hold
58.6%
Sell
6.9%

More PFE News

TipRanks 1d
Pfizer upgraded to Sector Perform from Underperform at RBC Capital

RBC Capital upgraded Pfizer (PFE) to Sector Perform from Underperform with a $25 price target Published first on TheFly – the ultimate source for real-time, ma...

24/7 Wall St. 1d
Earn $5,000+ Yearly With These 4 Dividend Stocks

Earn $5,000+ Yearly With These 4 Dividend Stocks By Vandita Jadeja Published Jun 9, 2:53PM EDT Quick Read Pfizer yields 6.70% and Verizon 6.23%, making them t...

Earn $5,000+ Yearly With These 4 Dividend Stocks
TipRanks 2d
Pfizer Obesity Franchise Shows Promise but Competition, Execution Risks Keep Rating at Hold and Price Target Unchanged at $26

Goldman Sachs analyst Asad Haider has maintained their neutral stance on PFE stock, giving a Hold rating on June 7. Asad Haider has given his Hold rating due t...

TipRanks 2d
Pfizer-Backed EV-309 Trial Targets Bladder-Sparing Edge in Muscle-Invasive Cancer

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer-Backed Bladder Cancer Study Pits Novel Combo Against Standard Care This Phase 3 t...

TipRanks 3d
Pfizer says FDA approves expanded indication for Hympavzi

Pfizer (PFE) announced that the U.S. FDA has approved an expanded indication for Hympavzi to include the treatment of patients with hemophilia A or B 12 years a...

TipRanks 3d
Pfizer presents results from Phase 2b studies of berobenatide

Pfizer (PFE) presented detailed results from multiple Phase 2b studies of berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agon...

Nasdaq 4d
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.

Key Points Pfizer’s net income is under pressure, and likely will be for the foreseeable future. Although its replenished pipeline and portfolio should help,...

Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.